Luc Sterkman

Caelus Pharmaceuticals BV operates as a biotechnology company that develops microbiome therapeutics for the reduction of insulin resistance and prevention of type 2 diabetes in people with metabolic syndrome. The firm is dedicated to the commercialisation of functional food and pharmabiotic products for the prevention and early treatment of cardio metabolic diseases-based on the correlation between the intestinal microbiome and health. The company was founded by Willem de Vos and Max Nieuwdorp and is headquartered in Amsterdam, the Netherlands.